Lataa...
Alpelisib-Induced Diabetic Ketoacidosis- A Case Report
Background: Alpelisib, in combination with Fulvestrant, was approved in 2019 by the Food and Drug Administration for treatment of HR+, HER2- advanced or metastatic breast cancer in patients with PIK3CA mutation. a This combination is currently on phase III of study. One of the most common side effec...
Tallennettuna:
| Julkaisussa: | J Endocr Soc |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8090425/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.743 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|